Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Christopher Di Felice

Pulmonary Disease Cleveland, OH Medical Doctor

NPI 1396159687 CMS profile 488650

9500 Euclid Ave, Cleveland, OH 44195

Open in the dashboard

General payments

$20,017

69 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$19,094 paid to institutions, not to them · program year 2024

Through program year 2025, Christopher Di Felice of Cleveland, OH is reported in the CMS Open Payments database as having received $20,017 across 69 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $19,094 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 89th percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,858 25
2024 General $10,369 22
2023 General $2,103 3
2022 General $279 5
2021 General $144 1
2020 General $2,181 9
2019 General $83 4

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Christopher Di Felice
  • Pulmonary Disease median
  • Middle half of Pulmonary Disease
  • National median

In program year 2025, general payments to Christopher Di Felice were reported at $4,858. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.

Show as a table
Year Christopher Di Felice Pulmonary Disease median Middle half National median
2019 $83 $377 $109–$1,340 $163
2020 $2,181 $230 $56–$907 $114
2021 $144 $269 $68–$1,072 $132
2022 $279 $390 $100–$1,457 $149
2023 $2,103 $419 $114–$1,659 $160
2024 $10,369 $476 $123–$1,818 $164
2025 $4,858 $500 $124–$1,893 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Pulmonx Corporation $7,987 6 payments
  2. Noah Medical Corporation $5,458 34 payments
  3. Intuitive Surgical, Inc. $3,882 9 payments
  4. Covidien LP $2,181 9 payments
  5. Boston Scientific Corporation $426 7 payments
  6. Merck Sharp & Dohme Corporation $48 2 payments
  7. AstraZeneca Pharmaceuticals LP $19 1 payment
  8. Jazz Pharmaceuticals Inc. $16 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $7,750 4 payments
  2. Food and Beverage $5,937 52 payments
  3. Travel and Lodging $3,830 12 payments
  4. Education $2,500 1 payment
Products named General payments · program years 2019–2025
  1. ZEPHYR ENDOBRONCHIAL VALVE $7,987 6 payments
  2. GALAXY $5,458 34 payments
  3. Da Vinci Surgical System $3,882 9 payments
  4. CHARTIS CATHETER $2,237 3 payments
  5. ZEPHYR DELIVERY CATHETER $2,237 3 payments
  6. PULMONX CHARTIS TABLET CONSOLE $2,237 3 payments
  7. superDimension $2,181 9 payments
  8. GENERAL PULMONARY $144 1 payment
  9. Alair Bronchial Thermoplasty RF Controller $125 1 payment
  10. EXALT Model D $117 3 payments
  11. Other $123 6 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 10 billing codes

Paid by Medicare

$8,948

Medicare's payments for the services billed

Medicare patients

33

Average age 78

Services billed

110

15 women, 18 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Cancer 75%
COPD 61%
Ischemic heart disease 52%
Arthritis 52%
Chronic kidney disease 36%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

69 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pulmonary Disease in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record